Eczema- Pipeline Insight, 2025

DelveInsight’s, “Eczema- Pipeline Insight, 2025” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Eczema pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Eczema: Understanding

Eczema: Overview

Eczema, also known as atopic dermatitis, is the most common form of dermatitis. Genetic as well as environmental factors are thought to play a part in the pathogenesis. Eczema is most commonly seen in children but can be seen in adults. People with the disease tend to have dry, itchy skin that is prone to infection. Eczema is commonly known as the ""itch that rashes"" due to dry skin that leads to a rash as a result of scratching or rubbing. The most important treatment of eczema is skin hydration followed by topical steroids for flare-ups. The lifetime prevalence of atopic dermatitis is about 15-30% in children and 2-10% in adults. About 60% of cases will develop within the first year of life. The prevalence of atopic dermatitis is more common in rural rather than urban areas. This incidence which emphasizes the link to lifestyle and environment factors in the mechanisms of AD. Symptoms of eczema include: A red rash or red patches of skin, especially inside the folds of the elbows and knees, itching, dry skin, which can crack and possibly bleed. The location of eczema may change with age. In infants and young children, eczema is usually located on the cheeks, outside of the elbows and on the knees. In older children and adults, eczema is typically on the hands and feet, the arms and on the back of knees. Symptoms can be painful, including blisters, and the skin may change color. The itch associated with eczema can be severe, often interrupting sleep. Scratching of the skin may lead to an infection. Infants with eczema may rub against bedding or other things to relieve the itch. Allergists are specially trained to treat skin conditions, such as eczema, which are often related to an allergic response. Children and adults diagnosed with eczema can manage the condition with the guidance of an allergist. In cases of moderate or severe eczema, an allergist may recommend prescription medication, including topical steroids and/or antihistamines. Milder cases may be treated with ointments, such as petroleum jelly, and moisturizers. Those should be applied daily, even when the skin appears clear, to help prevent dryness. People with eczema should avoid harsh cleansers, drink water often, wear gloves in cold weather, and avoid wearing materials such as wool, which could irritate the skin. Flare-ups of eczema can be caused by foods, cosmetics, soaps, wool, dust mites, mold, pollen, dog or cat dander, dry climate and other variables.

""Eczema- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Eczema pipeline landscape is provided which includes the disease overview and Eczema treatment guidelines. The assessment part of the report embraces, in depth Eczema commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Eczema collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Eczema R&D. The therapies under development are focused on novel approaches to treat/improve Eczema.

Eczema Emerging Drugs Chapters

This segment of the Eczema report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Eczema Emerging Drugs

• Amlitelimab: Kymab

Amlitelimab SAR445229 (formerly KY1005) is a human monoclonal antibody that targets OX40L, a key regulator of the immune system. Amlitelimab is designed to rebalance the immune system by blocking inappropriate activation and proliferation of ‘pro-inflammatory’ effector T cells and promoting expansion of ‘anti-inflammatory’ regulatory T cells, without broad suppression of the immune system. It is believed this mechanism-of-action means Amlitelimab could be applicable to a range of autoimmune and inflammatory diseases. In Phase I clinical trial in healthy volunteers, Amlitelimab was able to block T cell-driven skin inflammation while being well tolerated. It is believed the immune-modulating mechanism of Amlitelimab has broad potential therapeutic application in multiple diseases caused by immune dysregulation. Currently, the drug is being developed in the Phase II stage of clinical trial evaluation for the treatment of Eczema.

• BX 005: BiomX

BX005, a topical phage cocktail that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease. In preclinical in vitro studies, BX005 was shown to be active against over 90% of strains of S. aureus isolated from the skin of subjects from U.S. and Europe, including antibiotic resistant strains. Currently, the drug is being developed in the Phase I/II stage of clinical trial evaluation for the treatment of Atopic Dermatitis.

• LP 0145: LEO Pharma

LP 0145, is an anti-inflammatory monoclonal antibody under development for atopic dermatitis. Currently, the drug is being developed in the Phase II stage of clinical trial evaluation for the treatment of Eczemas.

Further product details are provided in the report……..

Eczema: Therapeutic Assessment

This segment of the report provides insights about the different Eczema drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Eczema

There are approx. 100+ key companies which are developing the therapies for Eczema. The companies which have their Eczema drug candidates in the most advanced stage, i.e. phase II include, LEO Pharma.

• Phases

DelveInsight’s report covers around 100+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Eczema pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Eczema: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Eczema therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Eczema drugs.

Eczema Report Insights

• Eczema Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Eczema Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Eczema drugs?
• How many Eczema drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Eczema?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Eczema therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Eczema and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Kymab
• BiomX
• LEO Pharma
• GlaxoSmithKline
• Arjil Pharmaceuticals
• SCM Lifescience
• Sun Pharmaceutical Industries
• Brickell Biotech Inc
• Dermira
• AstraZeneca
• Kyowa Kirin
• UCB Biopharma
• Arcutis Biotherapeutics

Key Products

• Amlitelimab
• BX 005
• LP 0145
• GSK 1070806
• AR 100
• SCM AGH
• SCD-044
• BBI 02
• Lebrikizumab
• Benralizumab
• UCB9741
• ARQ-151